Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.
about
Antiphospholipid syndrome in renal transplantation.Extra-renal manifestations of complement-mediated thrombotic microangiopathies.36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature.Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report.Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy.Eculizumab in Transplant-Associated Thrombotic Microangiopathy.The Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome.Eculizumab in secondary atypical haemolytic uraemic syndrome.Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches.Top 10 clinical research developments in antiphospholipid syndrome.Antiphospholipid syndrome: an update.Kidney transplantation in highly sensitized patients.Antiphospholipid syndrome, antiphospholipid antibodies and solid organ transplantation.Emerging Therapies in Antiphospholipid Syndrome.Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.Endothelial cells: source, barrier, and target of defensive mediators.Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.The role of complement inhibition in kidney transplantation.Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?Transplant glomerulopathy.AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game.Eculizumab Prevents Recurrent Antiphospholipid Antibody Syndrome and Enables Successful Renal TransplantationThrombotic microangiopathy after renal transplantation: Current insights in and recurrent disease
P2860
Q33413394-A741F331-F0E0-4E5E-B2E2-D919F995C2EAQ33417814-F2DED34B-7FF8-4EF0-BAE2-427569B4F2C0Q33418663-CDD84C38-7E72-4A9A-8958-651B9A2E5900Q33419171-E373EDFF-B967-4BF1-AE58-61864A5DF2D3Q33424902-B00A869D-8FD0-45BC-A66F-687E7E49F0BAQ33425079-EBE7082C-FA8F-4D2E-A25C-1325F5983DFAQ33431097-359D72C6-B793-428E-9E8C-A4BBF450D8EEQ33620588-C18FFCCD-B629-40AC-B4F8-C8D2D9E7C41BQ35621012-AB3A0E10-0B58-41B4-B43B-0317DDB5CBD4Q38135335-BAAE439C-7B99-4BCB-AC3B-938F6D3692B7Q38410376-67209C62-D81B-4594-8058-7F56E11C03F9Q38455229-26C2E8ED-6909-4009-B042-D832930E4F8BQ38544987-AE2C7B23-74D1-465D-BB87-D30B1E385993Q38782057-F577FBEC-7F20-4ADD-A973-AFD2C49A1ABCQ38930294-0AB8648A-D3E7-4339-BBFD-D81F50CE0347Q38991026-2B00649D-7B1E-4E55-AD0D-CE9C450762A6Q39968188-65FD743A-3590-4DFE-BE7F-326B03D38659Q42086661-C57DDF9F-F0AA-45DE-9AC3-6D8D0F98938DQ47640137-9085252E-5D34-4E9F-A0A1-5C26629CFDE0Q47720351-A56301C4-305E-4CEE-B025-5F0338AA1B42Q47998109-09F6B389-B7AA-4AE7-A205-05B2986A85A0Q48035289-D3598044-CCF1-44C2-9CEA-AB37D9DFE766Q50063069-48B2A168-1E94-46F0-B27A-8EFF7EBBEE64Q55068368-81A0A451-1CEE-4B5E-BA32-5AD184D3DAA2Q58048140-0DA9314A-058C-41B3-A579-C660A3A52EF5Q58754943-DFF6A7F7-AF80-4AF9-A07B-14F2784DBC09
P2860
Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Eculizumab improves posttransp ...... vent chronic vascular changes.
@ast
Eculizumab improves posttransp ...... vent chronic vascular changes.
@en
type
label
Eculizumab improves posttransp ...... vent chronic vascular changes.
@ast
Eculizumab improves posttransp ...... vent chronic vascular changes.
@en
prefLabel
Eculizumab improves posttransp ...... vent chronic vascular changes.
@ast
Eculizumab improves posttransp ...... vent chronic vascular changes.
@en
P2093
P2860
P356
P1476
Eculizumab improves posttransp ...... vent chronic vascular changes.
@en
P2093
A Del Bello
C Guilbeau-Frugier
C Legendre
D Anglicheau
F Martinez
L Esposito
L Rostaing
P2860
P304
P356
10.1111/AJT.12319
P407
P577
2013-06-13T00:00:00Z